Yabao Pharmaceutical Group Co Ltd

SHG:600351 China Drug Manufacturers - Specialty & Generic
Market Cap
$628.13 Million
CN¥4.61 Billion CNY
Market Cap Rank
#9902 Global
#2107 in China
Share Price
CN¥6.66
Change (1 day)
-0.30%
52-Week Range
CN¥5.66 - CN¥8.01
All Time High
CN¥14.53
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 a… Read more

Yabao Pharmaceutical Group Co Ltd (600351) - Net Assets

Latest net assets as of September 2025: CN¥2.76 Billion CNY

Based on the latest financial reports, Yabao Pharmaceutical Group Co Ltd (600351) has net assets worth CN¥2.76 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.34 Billion) and total liabilities (CN¥585.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.76 Billion
% of Total Assets 82.48%
Annual Growth Rate 15.57%
5-Year Change 2.72%
10-Year Change 8.1%
Growth Volatility 44.53

Yabao Pharmaceutical Group Co Ltd - Net Assets Trend (1999–2024)

This chart illustrates how Yabao Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Yabao Pharmaceutical Group Co Ltd (1999–2024)

The table below shows the annual net assets of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024.

Year Net Assets Change
2024-12-31 CN¥2.89 Billion -3.29%
2023-12-31 CN¥2.99 Billion -0.44%
2022-12-31 CN¥3.01 Billion +1.45%
2021-12-31 CN¥2.96 Billion +5.15%
2020-12-31 CN¥2.82 Billion +3.45%
2019-12-31 CN¥2.72 Billion -9.57%
2018-12-31 CN¥3.01 Billion +3.37%
2017-12-31 CN¥2.91 Billion +6.74%
2016-12-31 CN¥2.73 Billion +1.95%
2015-12-31 CN¥2.68 Billion +47.15%
2014-12-31 CN¥1.82 Billion +7.29%
2013-12-31 CN¥1.70 Billion +5.00%
2012-12-31 CN¥1.62 Billion +39.41%
2011-12-31 CN¥1.16 Billion +15.58%
2010-12-31 CN¥1.00 Billion +11.45%
2009-12-31 CN¥899.55 Million +8.34%
2008-12-31 CN¥830.32 Million +118.46%
2007-12-31 CN¥380.08 Million +13.61%
2006-12-31 CN¥334.54 Million -5.60%
2005-12-31 CN¥354.37 Million +4.79%
2004-12-31 CN¥338.16 Million +6.25%
2003-12-31 CN¥318.26 Million +14.56%
2002-12-31 CN¥277.81 Million +202.48%
2001-12-31 CN¥91.84 Million +7.24%
2000-12-31 CN¥85.64 Million +10.35%
1999-12-31 CN¥77.61 Million --

Equity Component Analysis

This analysis shows how different components contribute to Yabao Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 125621790087.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.25 Billion 43.28%
Common Stock CN¥720.00 Million 24.89%
Other Comprehensive Income CN¥286.75 Million 9.91%
Other Components CN¥633.97 Million 21.92%
Total Equity CN¥2.89 Billion 100.00%

Yabao Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Yabao Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Shinkong Synthetic Fiber Corp
TW:1409
 		$539.09 Million
National Healthcare Properties, Inc.
NASDAQ:NHPAP
 		$539.21 Million
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
 		$539.38 Million
Ingentec Corporation
TWO:4768
 		$539.43 Million
Indian Overseas Bank
NSE:IOB
 		$539.06 Million
HeNan Splendor Science & Technology Co Ltd
SHE:002296
 		$539.03 Million
Tibet GaoZheng Explosive Co Ltd
SHE:002827
 		$538.95 Million
KATITAS CO., Ltd.
PINK:KTITF
 		$538.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Yabao Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,976,188,510 to 2,892,638,654, a change of -83,549,856 (-2.8%).
  • Net income of 242,688,462 contributed positively to equity growth.
  • Dividend payments of 113,565,124 reduced retained earnings.
  • Share repurchases of 237,740,338 reduced equity.
  • Other comprehensive income increased equity by 286,748,497.
  • Other factors decreased equity by 261,681,353.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥242.69 Million +8.39%
Dividends Paid CN¥113.57 Million -3.93%
Share Repurchases CN¥237.74 Million -8.22%
Other Comprehensive Income CN¥286.75 Million +9.91%
Other Changes CN¥-261.68 Million -9.05%
Total Change CN¥- -2.81%

Book Value vs Market Value Analysis

This analysis compares Yabao Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.66x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 47.62x to 1.66x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 CN¥0.14 CN¥6.66 x
2000-12-31 CN¥0.14 CN¥6.66 x
2001-12-31 CN¥0.16 CN¥6.66 x
2002-12-31 CN¥0.49 CN¥6.66 x
2003-12-31 CN¥0.54 CN¥6.66 x
2004-12-31 CN¥0.55 CN¥6.66 x
2005-12-31 CN¥0.59 CN¥6.66 x
2006-12-31 CN¥0.58 CN¥6.66 x
2007-12-31 CN¥0.67 CN¥6.66 x
2008-12-31 CN¥1.36 CN¥6.66 x
2009-12-31 CN¥1.35 CN¥6.66 x
2010-12-31 CN¥1.57 CN¥6.66 x
2011-12-31 CN¥1.77 CN¥6.66 x
2012-12-31 CN¥2.42 CN¥6.66 x
2013-12-31 CN¥2.42 CN¥6.66 x
2014-12-31 CN¥2.66 CN¥6.66 x
2015-12-31 CN¥3.87 CN¥6.66 x
2016-12-31 CN¥3.33 CN¥6.66 x
2017-12-31 CN¥3.57 CN¥6.66 x
2018-12-31 CN¥3.69 CN¥6.66 x
2019-12-31 CN¥3.49 CN¥6.66 x
2020-12-31 CN¥3.61 CN¥6.66 x
2021-12-31 CN¥3.80 CN¥6.66 x
2022-12-31 CN¥3.86 CN¥6.66 x
2023-12-31 CN¥3.90 CN¥6.66 x
2024-12-31 CN¥4.02 CN¥6.66 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Yabao Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 8.39%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.04%
  • • Asset Turnover: 0.76x
  • • Equity Multiplier: 1.23x
  • Recent ROE (8.39%) is below the historical average (9.04%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 8.79% 5.41% 0.65x 2.50x CN¥-938.85K
2000 18.25% 10.87% 0.60x 2.78x CN¥6.56 Million
2001 20.75% 11.62% 0.59x 3.02x CN¥9.31 Million
2002 7.16% 9.15% 0.48x 1.65x CN¥-7.72 Million
2003 8.41% 6.69% 0.56x 2.24x CN¥-4.72 Million
2004 10.19% 5.24% 0.64x 3.06x CN¥596.56K
2005 7.41% 3.55% 0.60x 3.45x CN¥-8.53 Million
2006 6.76% 2.94% 0.73x 3.13x CN¥-10.45 Million
2007 12.51% 4.57% 0.92x 2.98x CN¥9.03 Million
2008 10.70% 6.81% 0.75x 2.10x CN¥5.62 Million
2009 14.81% 8.69% 0.67x 2.53x CN¥41.97 Million
2010 14.63% 12.21% 0.49x 2.47x CN¥45.70 Million
2011 16.34% 11.21% 0.73x 1.99x CN¥72.35 Million
2012 7.02% 8.87% 0.44x 1.80x CN¥-47.70 Million
2013 7.02% 7.27% 0.51x 1.90x CN¥-50.15 Million
2014 9.39% 9.00% 0.59x 1.76x CN¥-11.09 Million
2015 8.29% 10.75% 0.49x 1.59x CN¥-45.96 Million
2016 0.86% 1.25% 0.43x 1.60x CN¥-239.91 Million
2017 7.13% 7.83% 0.59x 1.56x CN¥-80.67 Million
2018 9.44% 9.37% 0.60x 1.67x CN¥-16.31 Million
2019 0.40% 0.35% 0.71x 1.60x CN¥-258.10 Million
2020 3.86% 4.13% 0.65x 1.44x CN¥-170.47 Million
2021 6.39% 6.77% 0.68x 1.39x CN¥-105.61 Million
2022 3.52% 3.85% 0.66x 1.39x CN¥-192.35 Million
2023 6.71% 6.86% 0.76x 1.29x CN¥-98.03 Million
2024 8.39% 9.04% 0.76x 1.23x CN¥-46.58 Million

Industry Comparison

This section compares Yabao Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Yabao Pharmaceutical Group Co Ltd (600351) CN¥2.76 Billion 8.79% 0.21x $539.06 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million